Watchlist Price Alert

Ginkgo Bioworks Inc. (DNA)

NYSE: DNA · Real-Time Price · USD

8.12

-0.19 (-2.29%)

At close: May 13, 2025, 3:59 PM

8.11

-0.06%

After-hours: May 13, 2025, 07:50 PM EDT

-2.29% (1D)

Bid	7.98
Market Cap	474.99M
Revenue (ttm)	227.04M
Net Income (ttm)	-547.03M
EPS (ttm)	-8.91
PE Ratio (ttm)	-0.91
Forward PE	-2.08
Analyst	Hold

Ask	8.21
Volume	1,008,872
Avg. Volume (20D)	1,599,150
Open	8.40
Previous Close	8.31
Day's Range	7.79 - 8.36
52-Week Range	5.00 - 38.60
Beta	1.29

About DNA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DNA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DNA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Ginkgo Bioworks has released their quartely earnings on May 6, 2025:

Revenue of $48M exceeds estimates by $6.74M, with 26.50% YoY growth.

EPS of -1.68 misses estimates by -0.45, with 47.50% YoY growth.

Why Price Moved

6 days ago

+14.73%

Ginkgo Bioworks shares are trading higher after th... Unlock content with Pro Subscription

1 month ago

+11.23%

Shares of healthcare technology stocks are trading higher. Some stocks in the sector rose after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.

News

5 days ago · businesswire.com

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care secto...

1 week ago · seekingalpha.com

Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2025 Results Conference Call May 6, 2025 5:00 PM ET Company Participants Daniel Marshall - Sr. Manager, Communications and Ownership Jason Kelly - Co-Foun...

1 week ago · zacks.com

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of $3.20 per share a year ago.

1 week ago · businesswire.com

Twist Bioscience Spins Out DNA Data Storage as Independent Company

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

1 week ago · zacks.com

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade

The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $7.37, representing a -0.14% change from its previous close.

2 weeks ago · zacks.com

Ginkgo Bioworks Holdings, Inc. (DNA) Rises Yet Lags Behind Market: Some Facts Worth Knowing

In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.60, marking a +0.8% move from the previous day.

3 weeks ago · accessnewswire.com

Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

- Pivot to U.S.-based Supply Chain for Critical Input Materials Completed - STONY BROOK, NY / ACCESS Newswire / April 21, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company")...

1 month ago · foxbusiness.com

23andMe probe launched to prevent customer DNA data from being sold to China or other bad actors

Sen. Bill Cassidy is probing 23andMe, which recently filed for bankruptcy protection, to ensure the company does not sell customer data to China or other foreign adversaries.

1 month ago · accessnewswire.com

Focus Graphite Advanced Materials Commences Work Program with AETC for C4V Digital DNA(TM) Testing and Strategic Specialty Applications

Exclusion of Canadian natural graphite from President Trump's "Liberation Day" U.S. Tariffs underscores urgency to fast-track testing and qualification with industry partners. OTTAWA, ON / ACCESS News...

1 month ago · accessnewswire.com

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

STONY BROOK, NY / ACCESS Newswire / April 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on April 7, 2025, it received a...

Load More News